Neutropenia Treatment Market Overview:
The global neutropenia market size was valued at $12,602.5 million in 2019, and is expected to reach $19,303.1 million by 2027, with a CAGR of 5.4% during the forecast period.
Neutropenia is a disease in which the amount of white blood cells (neutrophils) in the blood supply is decreased, reducing the capacity of the body to combat infections. Neutropenia is defined as an absolute count of neutrophils (ANC) below 1500 per microliter (1500/microL); severe neutropenia is defined as an ANC below 500/microL.
The neutropenia market is expected to register a substantial growth in the future, owing to rise in incidences of cancer cases. In addition, increase in R&D efforts by companies to develop novel therapies for treatment of neutropenia is expected to boost the market growth during the forecast period.
However, high cost of treatment of neutropenia and stringent rules and regulations for product approvals are anticipated to hamper the neutropenia treatment market growth during the forecast period. On the contrary, transitional shift from branded drugs to low cost biosimilars is expected to provide remunerative opportunities for the market players.
The neutropenia cancer market is segmented on the basis of treatment and distribution channel. By treatment, it is categorized into colony-stimulating factor, antibiotics, and antifungals. Colony-stimulating factors are secreted glycoproteins. These bind to receptor proteins on the surface of hematopoietic stem cells. The colony-stimulating factors are of two types, namely, granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF).
By Treatment
Colony-stimualting factors is projected as one of the most lucrative segments.
On the basis of distribution channel, it is divided into hospitals pharmacies, retail pharmacies, and online pharmacies. Neutropenia treatment drugs are marketed by various sales channel such as pharmacies, within the hospitals. These medications are also offered by online providers through registered websites, which offer the ease of ordering medicines over the internet. The retail pharmacies segment is expected to dominate the global neutropenia market, owing to adequate supply of products and easy availability and accessibility of retail pharmacies. Online pharmacies are projected to generate significant revenue in the global neutropenia treatment market during the forecast period.
By Distribution Channel
Hospital pharmcaies segment holds a dominant position in 2019 and online pharmacies segment will lead over the forecast period.
The global neutropenia treatment market is segmented on the basis of region into North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, and rest of Asia-Pacific), LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
North America accounted for the largest share in the global neutropenia treatment market. The neutropenia treatment market witnessed a vast growth in North America and is expected to dominate the market in the coming years. This is attributed to the increase in incidences of leukemia in the region. According to the International Agency for Research on Cancer, in 2018, 169,270 people are living with leukemia for five years and 58,876 new leukemia cases were diagnosed in North America. In addition, major key players of the market operate in North America. Further, the demand for neutropenia treatment in North America is dominated by the US. The dominance of the region is due to a rise in demand for medicinal needs for febrile neutropenia and introduction of new legislation for promotion and production of biosimilars.
Asia-Pacific is expected to witness highest growth rate in the market throughout the forecast period. Asia possesses high potential for the growth of neutropenia treatment market, owing to leukemia cases and number of patients undergoing first-line chemotherapy treatment.
According to the Lancet Oncology journal, globally, 58% of new cancer patients (9.8 million out of 17 million) received chemotherapy in 2018. The report estimated that the number of new cancer cases would increase to 26 million in 2040, of which 53% (15 million out of 26 million)—an estimated 5.2 million new cancer cases — are likely to undergo chemotherapy. More than one-third of the 15 million citizens needing chemotherapy in 2040 would be residing in eastern Asia (5.2 million, 35%). In comparison, 12% (1.7 million) would live in South Central Asia, 10% (1.4 million) in South East Asia, 6% (922,452).
Global Neutropenia Treatment Market Segmentation
The global neutropenia treatment market is segmented on the basis of treatment distribution channel and region. By treatment, the market is segmented into colony-stimulating factor, antibiotics, antifungals and antivirals. By distribution channel, it is divided into hospital pharmacies, retail pharmacies and online pharmacies. Region wise, it is analyzed across North America, Asia-Pacific, Europe, and LAMEA.
Asia-Pacific is expected to witness highest growth rate in the market throughout the forecast period. Increase in incidences of leukemia will drive the overall market during the forecast period.
Segment review
On the basis of treatment, the colony-stimulating factor segment was the largest revenue contributor in 2019, and is anticipated to continue its dominance during the forecast period, owing to presence of major players who are focused on the development of colony-stimulating factor based drugs. In addition, colony-stimulating factor is a multifunctional cytokine and an inhibitor of hematopoietic stem cell proliferation.
On the basis of distribution channel, the hospital pharmacies segment held a dominant portion in the market, accounting for about 40.6% share of the global neutropenia treatment market in 2019.
The major companies profiled in this report include Amgen, BeyondSpring, Kyowa Kirin, Cellerant Therapeutics, Mylan N.V., Novartis AG, Partner Therapeutics, Pfizer, Spectrum Pharmaceuticals and Teva Pharmaceutical Industries Ltd. Other players in neutropenia market (not profiled in the report) include Myelo Therapeutics, and Enzychem Lifesciences Corporation Samsung Medical Center.
Key Benefits For Stakeholders
The study provides an in-depth analysis of the global neutropenia market size along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers neutropenia treatment market analysis from 2020 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global neutropenia market growth.
Key market players and their strategies are provided to understand the competitive outlook of the market.
Neutropenia Treatment Market, by Treatment Report Highlights
| Aspects | Details |
 By Treatment |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | TEVA PHARMACEUTICAL INDUSTRIES LTD., BEYONDSPRING INC., NOVARTIS AG, PARTNER THERAPEUTICS, INC., COHERUS BIOSCIENCES, INC., SPECTRUM PHARMACEUTICALS, INC., MYLAN N.V., PFIZER INC., KYOWA KIRIN, CELLERANT THERAPEUTICS, INC., AMGEN INC. |
Analyst Review
Neutropenia is a condition that occurs when body does not have enough neutrophils, an important white blood cell that helps fight against infections. The treatment for neutropenia is anticipated to witness a significant rise with discovery of biosimilar drugs, rise in incidences of leukemia cases, and favorable reimbursement policies.
Also, increase in research and development activities by key market players and transition from branded drugs to biosimilars for neutropenia treatment is expected to drive the market growth during the forecast period. Moreover, robust drug pipeline for neutropenia treatment market is expected to provide lucrative opportunities for advanced treatment options. However, high cost of treatment of neutropenia and stringent rules and regulations for product approvals are anticipated to hamper the market growth during the forecast period.
The total value of Neutropenia Treatment market was $ 12,602.5 million in 2019.
The forecast period in the report is from 2020-2027.
The market value of Neutropenia Treatment market in 2019 was $13,399 million.
The base year calculated is 2019 in the report.
Rise in R&D efforts by the key players to develop novel therpaies in the market is expected to drive the market growth during the forecast period.
The growth % of the Canada HER2-positive Metastatic Breast Cancer market is 5.4%.
Colony-stimulating factors segment holds the maximum market share.
Loading Table Of Content...
